Standout Papers

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced es... 2022 2026 2023 2024145
  1. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (2022)
    Jun Liu, Yang Yang et al. Journal for ImmunoTherapy of Cancer
  2. Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial. (2022)
    Rong Hua, Hezhong Chen et al. PubMed

Immediate Impact

53 standout
Sub-graph 1 of 23

Citing Papers

H3K18 Lactylation Potentiates Immune Escape of Non–Small Cell Lung Cancer
2024 Standout
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
2 intermediate papers

Works of Bentong Yu being referenced

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
2021
TRIM59 regulates autophagy through modulating both the transcription and the ubiquitination of BECN1
2018

Author Peers

Author Last Decade Papers Cites
Bentong Yu 526 390 230 445 56 1.2k
Kota Ishizawa 648 501 166 290 44 1.4k
Yuko Kitagawa 520 397 329 562 105 1.5k
Hong Zhu 314 354 157 235 60 1.2k
Yi‐Ming Shyr 618 383 146 582 65 1.5k
Itzhak Avital 344 480 444 449 42 1.5k
Zhen Liu 313 650 286 235 81 1.5k
Wei Xu 390 623 417 311 70 1.4k
Yi‐Wei Xu 204 451 209 329 95 1.2k
Hye Won Lee 309 477 257 163 52 1.2k
Shunli Shen 271 419 364 327 56 1.3k

All Works

Loading papers...

Rankless by CCL
2026